165 related articles for article (PubMed ID: 37453958)
1. Differential distribution of actual and surrogate oncotype DX recurrence scores in breast cancer patients by age, menopausal status, race, and body mass index.
Mohamed A; Olsson LT; Geradts J
Breast Cancer Res Treat; 2023 Oct; 201(3):447-460. PubMed ID: 37453958
[TBL] [Abstract][Full Text] [Related]
2. Menopausal status does not predict Oncotype DX recurrence score.
Carr DN; Vera N; Sun W; Lee MC; Hoover S; Fulp W; Acs G; Laronga C
J Surg Res; 2015 Sep; 198(1):27-33. PubMed ID: 26095420
[TBL] [Abstract][Full Text] [Related]
3. Relationship of Oncotype Dx score with tumor grade, size, nodal status, proliferative marker Ki67 and Nottingham Prognostic Index in early breast cancer tumors in Saudi Population.
Durrani S; Al-Mushawa F; Heena H; Wani T; Al-Qahtani A
Ann Diagn Pathol; 2021 Apr; 51():151674. PubMed ID: 33360027
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Oncotype DX With Modified Magee Equation Recurrence Scores in Low-Grade Invasive Carcinoma of Breast.
Hou Y; Zynger DL; Li X; Li Z
Am J Clin Pathol; 2017 Aug; 148(2):167-172. PubMed ID: 28898988
[TBL] [Abstract][Full Text] [Related]
5. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
[TBL] [Abstract][Full Text] [Related]
6. Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer.
Morales Murillo S; Gasol Cudos A; Veas Rodriguez J; Canosa Morales C; Melé Olivé J; Vilardell Villellas F; Sanchez Guzman DR; Iglesias Martínez E; Salud Salvia A
Breast; 2021 Apr; 56():35-41. PubMed ID: 33601299
[TBL] [Abstract][Full Text] [Related]
7. Pathobiologic Stratification of Oncotype DX Recurrence Scores and Comparative Validation of 3 Surrogate Models.
Mohamed A; Kousar A; Wong J; Vohra N; Muzaffar M; Geradts J
Arch Pathol Lab Med; 2022 Oct; 146(10):1258-1267. PubMed ID: 35119458
[TBL] [Abstract][Full Text] [Related]
8. Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer.
Chen C; Dhanda R; Tseng WY; Forsyth M; Patt DA
J Oncol Pract; 2013 Jul; 9(4):182-7. PubMed ID: 23942918
[TBL] [Abstract][Full Text] [Related]
9. Discordance of Oncotype DX scores in synchronous bilateral and unilateral multifocal breast cancers.
Wang J; Chen H; Koenig J; Wu Y; Bedrosian I; Arun B; Ding Q; Khazai L; Resetkova E; Huo L; Sneige N; Albarracin C
Breast Cancer Res Treat; 2024 Jan; 203(1):73-83. PubMed ID: 37751078
[TBL] [Abstract][Full Text] [Related]
10. Using the Modified Magee Equation to Identify Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay (Oncotype DX Assay).
Hou Y; Tozbikian G; Zynger DL; Li Z
Am J Clin Pathol; 2017 Jun; 147(6):541-548. PubMed ID: 28449064
[TBL] [Abstract][Full Text] [Related]
11. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
Milburn M; Rosman M; Mylander C; Tafra L
Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
[TBL] [Abstract][Full Text] [Related]
12. Is there an association between body mass index and 21-gene recurrence score?
Pomponio M; Burkbauer L; Goldbach M; Keele L; Allison KC; Li YR; Nazarian SM; Tchou J
Surg Oncol; 2020 Sep; 34():74-79. PubMed ID: 32891357
[TBL] [Abstract][Full Text] [Related]
13. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score?
Auerbach J; Kim M; Fineberg S
Arch Pathol Lab Med; 2010 Nov; 134(11):1697-701. PubMed ID: 21043825
[TBL] [Abstract][Full Text] [Related]
14. Evaluation oncotype DX
Lashen A; Toss MS; Fadhil W; Oni G; Madhusudan S; Rakha E
Histopathology; 2023 Apr; 82(5):755-766. PubMed ID: 36631400
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer tumor heterogeneity has only little impact on the estimation of the Oncotype DX® recurrence score using Magee Equations and Magee Decision Algorithm™.
Remoué A; Conan-Charlet V; Deiana L; Tyulyandina A; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2021 Feb; 108():51-59. PubMed ID: 33245987
[TBL] [Abstract][Full Text] [Related]
16. Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer.
Tan AC; Li BT; Nahar K; Danieletto S; Fong ES; Currer T; Parasyn A; Middleton P; Wong H; Smart D; Rutovitz JJ; McCloud P; Hughes TM; Marx GM
Asia Pac J Clin Oncol; 2018 Apr; 14(2):e161-e166. PubMed ID: 28960862
[TBL] [Abstract][Full Text] [Related]
17. Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score.
Turner BM; Skinner KA; Tang P; Jackson MC; Soukiazian N; Shayne M; Huston A; Ling M; Hicks DG
Mod Pathol; 2015 Jul; 28(7):921-31. PubMed ID: 25932962
[TBL] [Abstract][Full Text] [Related]
18. Association of Race/Ethnicity and the 21-Gene Recurrence Score With Breast Cancer-Specific Mortality Among US Women.
Hoskins KF; Danciu OC; Ko NY; Calip GS
JAMA Oncol; 2021 Mar; 7(3):370-378. PubMed ID: 33475714
[TBL] [Abstract][Full Text] [Related]
19. Oncotype DX Breast Cancer recurrence score resists inter-assay reproducibility with RT
Schildgen V; Warm M; Brockmann M; Schildgen O
Sci Rep; 2019 Dec; 9(1):20266. PubMed ID: 31889145
[TBL] [Abstract][Full Text] [Related]
20. Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review.
Glasgow A; Sechrist H; Bomeisl P; Gilmore H; Harbhajanka A
Breast Cancer; 2021 Mar; 28(2):321-328. PubMed ID: 32951186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
